Ciphergen Biosystems,
Inc. (Nasdaq: CIPH) announced the discovery of two biomarkers that may aid
in the management of prostate cancer, including for the detection, staging,
and prediction of recurrence. These markers, a fragment of protein C
inhibitor (PCI) and complement factor 4 (C4a), were identified in two
separate studies, a multi-institutional study encompassing over 400 men and
a five-year longitudinal study following 104 patients after radical
prostatectomy. These studies demonstrated that PCI provides information
useful for the detection and staging of prostate cancer, and the combined
use of pre-surgery PCI, PSA, and C4a is predictive of prostate cancer
recurrence. The work was performed by Dr. Daniel Chan and Dr. Zhen Zhang of
the Johns Hopkins Medical Institutions as part of our research
collaboration.
"We are pleased with the progress of our ongoing collaborative prostate
cancer program with Johns Hopkins. These findings address a critical aspect
of the management of prostate cancer, as the ability to predict recurrence
can help physicians and patients understand better the aggressiveness of
disease," said Gail S. Page, President and CEO of Ciphergen. "The discovery
of PCI using Ciphergen's technology demonstrates its ability to identify
markers directly related to the disease process, since PCI is present in
seminal fluid and directly interacts with PSA. Further validation is
underway."
About Ciphergen
Ciphergen is dedicated to translating protein biomarkers and panels of
biomarkers into protein molecular diagnostic tests that improve patient
care. We are also focused on providing collaborative R&D services through
our Biomarker Discovery Center(R) laboratories for biomarker discovery for
new diagnostic tests as well as pharmacoproteomic services for improved
drug toxicology, efficacy and theranostic assays. Ciphergen develops,
manufactures and markets a family of ProteinChip(R) Systems and services
for clinical, research and process proteomics applications. ProteinChip
Systems enable protein discovery, validation, identification and assay
development to provide researchers with predictive, multi-marker assay
capabilities and a better understanding of biological function at the
protein level. Additional information about Ciphergen can be found at
ciphergen.
Safe Harbor Statement
Note Regarding Forward-Looking Statements: This press release contains
forward-looking statements. For purposes of the Private Securities
Litigation Reform Act of 1995 (the "Act"), Ciphergen disclaims any intent
or obligation to update these forward-looking statements, and claims the
protection of the Safe Harbor for forward-looking statements contained in
the Act. Examples of such forward-looking statements include statements
regarding the usefulness of certain biomarkers to predict the recurrence of
disease and the ability of Ciphergen to use such biomarkers in the creation
of diagnostic tests. Actual results may differ materially from those
projected in such forward-looking statements due to various factors,
including the risk that Ciphergen may not be able to develop diagnostic
tests based on the discoveries of certain biomarkers. Investors should
consult Ciphergen's filings with the Securities and Exchange Commission,
including its Form 10-K filed March 17, 2006, for further information
regarding these and other risks related to the Company's business.
Ciphergen, ProteinChip and Biomarker Discovery Center are
registered trademarks of Ciphergen Biosystems, Inc.
Ciphergen Biosystems, Inc.
ciphergen/